Please select your Region.
Please select your Region.
Dec 21, 2007
Despite having world’s largest number of diabetic patients
(40.9 million: *IDF), the number of SMBG users in India is
very small. One out of ten people living in Mumbai is said
to be pre-diabetic, and the number of diabetic patients has
been on the increase in line with the development of the Indian
economy.
It is expected that the number of SMBG users will increase
at an accelerated pace in tandem with a rise in household
income levels as the Indian economy grows. This joint venture
between NPIL, with its sales network throughout India and
established brand image, and ARKRAY with an established reputation
of being a pioneer of SMBG will make a full-fledged entry
to the Indian market as well as gaining an increased market
share in India.
* International Diabetes Federation
| Company name | ARKRAY PIRAMAL Medical Private Limited |
|---|---|
| Headquarters | Republic of India, Maharashtra state, Mumbai |
| Capital : | 60 million INR (Approx. 180 million yen) |
| Division of capital | ARKRAY 51% NPIL 49% |
| Sales areas (plan) | Main Indian cities (Mumbai, Delhi, Kolkata, Chennai, Bangalore, Hyderabad, Surat, Ludhiana) |
| Company name | Nicholas Piramal India Limited |
|---|---|
| President | Ajay G. Piramal |
| Headquarters | Nicholas Piramal Tower, Ganpatra Kadam Marg, Lower Parel, Mumbai 400 013 India |
| Telephone | +91-22-3046-6412(Vijay Sathye, Sagar Gokani) |
| Establishment | 26 April 1947 |
| Capital | 801.7million INR (approx. 2.4 billion JPY) |
| Staff | Approx. 7,500 |
| Business type | Pharmaceutical |
| Business bases | Mumbai, Delhi, Kolkata, Chennai, Bangalore, Hyderabad, Surat, Ludhiana |
沪公网安备 31011502009006号
